IL-6 Antibody

Recombinant Cotton Rat IL‑6 (Catalog # 561-R6) stimulates proliferation in the T1165.85.2.1 mouse plasmacytoma cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Cotton Rat IL‑6 (0.25 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Cotton Rat IL‑6 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF561). The ND50 is typically 0.03‑0.12 µg/mL.

• Reactivity: Cr
• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

IL-6 Antibody Summary

• Immunogen: E. coli-derived recombinant cotton rat IL‑6
  Leu25-Asn212
  Accession # AAL18819
• Specificity: Detects cotton rat IL-6 in direct ELISAs and Western blots. In direct ELISAs, approximately 20% cross‑reactivity with recombinant mouse IL-6 and recombinant rat IL-6 is observed and less than 5% cross-reactivity with recombinant porcine IL-6 and recombinant human IL-6 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: IL6
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 0.03-0.12 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-6 Antibody

• B-cell differentiation factor
• B-cell stimulatory factor 2
• BSF2
• BSF-2
• CDF
• CTL differentiation factor
• HSF
• hybridoma growth factor
• IFNB2
• IFN-beta-2
• IL6
• IL-6
• Interferon beta-2
• interleukin 6 (interferon, beta 2)
• interleukin BSF-2
• interleukin-6
• MGI-2A

Background

Interleukin 6 (IL-6) is a pleiotropic alpha -helical cytokine that plays important roles in acute phase reactions, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 activity is central to the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. It is secreted by multiple cell types as a 22 kDa‑28 kDa phosphorylated and variably glycosylated molecule (1‑4). Mature cotton rat IL-6 is 186 amino acids (aa) in length and shares 39%, 70%, and 75% aa sequence identity with human, mouse, and rat IL-6 (5). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R, triggering IL-6 R association with gp130 and gp130 dimerization (6). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (7). Soluble forms of IL-6 R are generated by both alternate splicing and proteolytic cleavage (3). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R elicit responses from gp130-expressing cells that lack cell surface IL-6 R (3). Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous while that of IL-6 R is predominantly restricted to hepatocytes, leukocytes, and lymphocytes (3). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R but not from other cytokines that utilize gp130 as a coreceptor (4, 8).

1. Van Snick, J. (1990) Annu. Rev. Immunol. 8:253.
2. Hodge, D.R. et al. (2005) Eur. J. Cancer 41:2502.
3. Jones, S.A. (2005) J. Immunol. 175:3468.
4. Rose-John, S. et al. (2006) J. Leukoc. Biol. 80:227.
5. Accession # AAL11819.
6. Murakami, M. et al. (1993) Science 260:1808.
7. Muller-Newen, G. (2003) Sci. STKE 2003:PE40.
8. Mitsuyama, K. et al. (2006) Clin. Exp. Immunol. 143:125.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-6 Antibody (AF561)(2)

Publications using AF561

• Russell Marsha S, Creskey Marybeth, Muralidharan Abenaya et al. Unveiling Integrated Functional Pathways Leading to Enhanced Respiratory Disease Associated With Inactivated Respiratory Syncytial Viral Vaccine. Frontiers in Immunology 3/29/2019 [PMID: 30984178]
• Kim D, Niewiesk S Synergistic induction of interferon alpha through TLR-3 and TLR-9 agonists identifies CD21 as interferon alpha receptor for the B cell response. PLoS Pathog, 2013-03-14;9(3):e1003233. 2013-03-14 [PMID: 23516365] (Neutralization, Cotton Rat)

FAQs for IL-6 Antibody (AF561). (Showing 1 - 1 of 1 FAQs).

1. I was wondering if you know of any blocking antibodies against IL-6 or VEGF-C that can be used in cell culture to quench these cytokines?
   • We have no antibodies that are currently known to show blocking antibodies to VEGF-C. Please see this link to our IL-6 antibodies with blocking/neutralizing activity can be found at this link.

Bioinformatics

• Gene Symbol: IL6
• Uniprot:
  • AAL18819()